公司董事、副总裁、董事会秘书林强先生保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 公司董事、副总裁、董事会秘书林强先生，持有本公司股份6,264,880股（占 本公司总股本比例1.56%）计划在减持计划公告之日起十五个交易日后的三个月 内以集中竞价交易或大宗交易方式，减持所持有的本公司股份不超过1,566,220 股（占本公司总股本比例0.39%）。 四川金石亚洲医药股份有限公司（以下简称"公司"）于近日收到公司董事、 副总裁、董事会秘书林强先生出具的《关于拟减持四川金石亚洲医药股份有限公 司股份的告知函》，现将有关情况公告如下： 一、股东基本情况 | 姓名 | 任职情况 | 持股数量（股） | 占公司总股本的比例 | | --- | --- | --- | --- | | 林强 | 董事、副总裁、董事会秘书 | 6,264,880 | 1.56% | 证券代码：300434 证券简称：金石亚药 公告编号：2025-022 四川金石亚洲医药股份有限公司 关于董事兼高级管理人员减持股份的预披露 ...

Group 1 - The CRO concept sector experienced a decline of 1.65%, ranking among the top declines in the concept sector, with notable declines from companies such as Saint Noble Bio, Meinohua, and Ruizhi Medicine [1][2] - Among the CRO concept stocks, 10 stocks saw price increases, with Wanbang Pharmaceutical, Puni Testing, and Huace Testing leading the gains at 6.96%, 3.37%, and 2.25% respectively [1][2] - The CRO concept sector faced a net outflow of 1.109 billion yuan in main funds, with 48 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock was WuXi AppTec, with a net outflow of 337 million yuan, followed by Lianhua Technology, Ruizhi Medicine, and Kailai Ying with net outflows of 136 million yuan, 105 million yuan, and 86 million yuan respectively [2][3] - The stocks with the highest net inflow included Huace Testing, Dongcheng Pharmaceutical, and Jinshi Yao, with net inflows of 29.24 million yuan, 23.51 million yuan, and 15.25 million yuan respectively [2][4] - The overall market sentiment reflected a mixed performance across various concept sectors, with brain-computer interface leading the gains at 6.63% while the CRO concept lagged behind [2][4]

证券代码：300434 证券简称：金石亚药 公告编号：2025-021 四川金石亚洲医药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 按照相关规定，本次分配预案公布后至实施前，若公司总股本由于增发新股、 股权激励行权、可转债转股等原因导致股份总数发生变动的，将按照分配总额不 变的原则，以公司未来实施利润分配方案时股权登记日的总股本为基数，对每股 分红比例进行调整。 2、公司自权益分派方案披露至实施期间公司股本总额未发生变化。 3、本次实施的股权分派方案与 2024 年年度股东大会审议通过的利润分配 方案一致。 4、本次实施的权益分派方案距离 2024 年年度股东大会审议通过的时间未 超过两个月。 二、权益分派方案 四川金石亚洲医药股份有限公司（以下简称"公司"或"本公司"）2024 年 年度权益分派方案已获2025年5月23日召开的2024年年度股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过权益分派方案情况 1、公司 2024 年年度权益分派方案已获 2025 年 5 月 23 日召开的 20 ...

2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 证券代码：300434 证券简称：金石亚药 公告编号：2025-020 四川金石亚洲医药股份有限公司 2、现场会议召开地点：杭州市滨江区江南大道 4760 号亚科中心公司会议室 3、会议召开方式：本次股东大会采取现场投票和网络投票相结合的方式 4、会议召集人：公司第五届董事会 5、会议主持人：公司董事长马益平先生 6、会议召开的合法、合规性：2025 年 4 月 23 日，公司第五届董事会第八 次会议审议通过《关于召开 2024 年年度股东大会的议案》，决议召开本次股东大 会，本次股东大会会议召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定。 （二）会议的出席情况 1、会议召开的时间 （1）现场会议召开时间：2025 年 5 月 23 日（星期五）下午 2：00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 23 ...

Group 1: Company Strategy and Development - The company adheres to a dual strategy of independent and collaborative research and development, enhancing its long-term development through strategic investments and internal resource integration [1] - The company aims to become a trusted and preferred provider of professional healthcare products, focusing on a unified operational system across R&D, marketing, and production [2] - The company plans to implement a four-pronged growth model encompassing OTC, prescription drugs, traditional Chinese medicine, and health products to support high-quality development [2] Group 2: Marketing and Sales Achievements - The company has established a comprehensive marketing system, covering over 3,000 chain pharmacies and approximately 240,000 cooperative chain stores, reaching over 90% of cities and 70% of districts nationwide [2] - The company’s online channel strategy includes partnerships with e-commerce platforms to enhance product accessibility and consumer engagement [2] Group 3: Financial Performance - In 2024, the pharmaceutical segment generated revenue of 915 million yuan, accounting for 82.96% of total revenue, with the "Kuaike" series contributing 612 million yuan, representing 55.49% of total revenue [3] - The company’s cold and flu medications account for approximately 56% of total revenue [4] Group 4: Product Development and Market Position - The "Kuaike" cold medicine has ranked first in the annual comprehensive statistics of non-prescription drugs in China for three consecutive years from 2021 to 2023 [3] - The company has successfully launched the "Kuaike Qing" oseltamivir capsules and has received re-listing permits for other products [1] Group 5: Future Plans and Challenges - The company is actively preparing for the flu season by optimizing production capacity and ensuring smooth supply channels [5] - The company is exploring opportunities in traditional Chinese medicine, developing high-quality products to enhance market share in this sector [5]

Group 1 - The chemical pharmaceutical sector experienced a significant rally, with Hendi Pharmaceutical (301211) rising over 10% [1] - Xinhua Pharmaceutical (000756) reached its daily limit up [1] - Other companies such as Jinshi Yiyao (300434), Haichuang Pharmaceutical, and Duori Pharmaceutical (301075) also saw increases [1]

Financial Performance - In 2024, the company achieved operating revenue of 1.102 billion yuan, a year-on-year decrease of 8.84% [5] - The net profit attributable to shareholders was 91.76 million yuan, down 27.29% year-on-year [5] - The basic earnings per share were 0.23 yuan per share [5] Key Financial Ratios - The net cash inflow from operating activities was 158 million yuan, an increase of 4.6% year-on-year [4] - The weighted average return on equity was 3.75%, a decrease of 1.65 percentage points year-on-year [4] - The gross profit margin was 57.44%, down 6.44% year-on-year [4] - The asset-liability ratio stood at 19.16%, and the net profit margin was 8.03% [4] Business Segment Performance - The core product "Kuaike" series in the cold medicine segment accounted for 55.49% of revenue but saw a year-on-year decline of 17.16% due to shrinking retail demand and competition from foreign products [4] - Revenue from health food and traditional Chinese medicine slices was 39.09 million yuan, down 7.98% year-on-year, with the new product "Jinxing Glucosamine Soft Capsule" not yet achieving scale [4] - Revenue from complete production lines was 147 million yuan, marking a significant year-on-year increase of 89.95% [4] Research and Development - In 2024, the company's R&D investment was 49.99 million yuan, accounting for 4.54% of revenue [6] - The consistency evaluation for Diclofenac Sodium Sustained-Release Tablets has entered the application stage, and the antiviral drug Oseltamivir Phosphate Capsules have been approved for market [6] - The company plans to accelerate the promotion of "Jinxing Glucosamine Soft Capsule" through e-commerce channels [6] Dividend Distribution - The company plans to distribute a cash dividend of 0.69 yuan per 10 shares (including tax) in 2024 [7] International Expansion - The mechanical segment is providing customized magnetron sputtering vacuum coating equipment to global clients, with a factory planned in Mexico to enhance hydrogen pipeline technology output capabilities [6]

Policy Developments - Seven departments, including the Ministry of Industry and Information Technology, issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", emphasizing the integration of artificial intelligence across the pharmaceutical supply chain [1] Drug and Device Approvals - Kangtai Biological announced that its subsidiary Minhai Biological's application for the marketing authorization of an adsorbed tetanus vaccine has been accepted by the National Medical Products Administration [2] - Hendi Pharmaceutical received approval for the marketing application of arginine ibuprofen, a non-steroidal anti-inflammatory drug with superior solubility and faster absorption compared to regular ibuprofen [3] - Tianyao Pharmaceutical's subsidiary obtained a drug registration certificate for injectable hydrocortisone sodium succinate, used for critical conditions such as allergic shock and severe adrenal insufficiency [4] Financial Reports - Wantai Biological reported a net loss of 52.78 million yuan in Q1 2025, with revenue of 401 million yuan, a year-on-year decline of 46.76%, primarily due to market adjustments and government procurement impacts [5] - Heng Rui Pharmaceutical's Q1 2025 report showed a revenue of 7.206 billion yuan, a year-on-year increase of 20.14%, and a net profit of 1.874 billion yuan, up 36.9%, largely due to a licensing payment from IDEAYA [6] - Kingstone Pharma reported a revenue of 291 million yuan in Q1 2025, down 19.65%, with a net profit of 62.85 million yuan, a decrease of 30.02% [8] - Baijun Medical achieved a revenue of 100 million yuan in Q1 2025, a 31.3% increase, with a net profit of 32.50 million yuan, up 290.69%, driven by stable sales of existing products and successful new product launches [9] Capital Market Activities - Tonghe Pharmaceutical plans to invest 11 million yuan to increase its stake in Hangzhou Boya Biomedical Co., Ltd., raising its ownership from 16.34% to 24.93% [10] - Chengyuan Biotechnology announced the completion of several million yuan in equity financing, aimed at upgrading its gene synthesis technology platform [11] Industry Developments - Zhang Wenhong's team announced significant progress in developing a broad-spectrum antiviral drug for monkeypox, which is set to enter clinical approval stages [12] - Qianxin Biotechnology signed a licensing agreement with Caldera Therapeutics for its long-acting dual antibody QX030N, granting global exclusive rights for development and commercialization [13] Public Sentiment Alerts - Weiming Pharmaceutical announced that its important subsidiary, Tianjin Weiming, was suspended from production and sales, which could trigger further risk warnings if production does not resume within three months [14]

Core Viewpoint - Sichuan Jinshi Asia Pharmaceutical Co., Ltd. (referred to as "Jinshi Asia Pharmaceutical" or "the company") reported a decline in both revenue and net profit for the fiscal year 2024 and the first quarter of 2025, primarily due to intensified competition in the cold medicine market and changes in medical policies [1][2]. Financial Performance - In 2024, the company achieved total revenue of 1.102 billion yuan, a year-on-year decrease of 8.84%, and a net profit of 91.76 million yuan, down 27.29% [1]. - For the first quarter of 2025, revenue was 291 million yuan, reflecting a 19.65% decline year-on-year, while net profit was 62.85 million yuan, a decrease of 30.02% [1][2]. Market Dynamics - The cold medicine market has become increasingly competitive, with a diverse range of products including traditional cold medicines, Chinese herbal medicines, and imported antiviral drugs, which has intensified market competition [1][2]. - The shift in patient treatment preferences towards hospital care during the 2024 flu season has led to a significant reduction in retail sales of cold medicines [2]. Business Structure - The company's reliance on the cold medicine category has exacerbated revenue volatility, as its core product line, the "Kuaike" cold medicine series, has seen a decline in demand following a period of heightened consumption [2]. - Despite attempts to diversify into health products and prescription drugs, these new business segments have not yet contributed significantly to overall revenue [2]. Product Concentration - Jinshi Asia Pharmaceutical's main business includes the research, production, and sales of over 90 drug production approvals and 7 health food production approvals, with the Kuaike cold medicine series being a major revenue source [3]. - The concentration of leading products in specific market segments provides a competitive advantage, but any adverse changes in raw material prices or market conditions could significantly impact the company's performance [3].